NCT05804279

Pharmacokinetics of BPDO-1603 or BPDO-16031 and BPDO-16033 Administration in Healthy Adults

Pharmacokinetics and Safety of BPDO-1603 or BPDO-16031 and BPDO-16033 Administration in Healthy Adults. Randomized, Open-label, Single-dose, Cross-over, Phase 1 Study

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Hyundai Pharm · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Pharmacokinetics and safety of BPDO-1603 or BPDO-16031 and BPDO-16033 administration in healthy adults. Randomized, open-label, single-dose, cross-over, Phase 1 study

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	BPDO-1603	donepezil/mematine

Timeline

• Start date: 2022-12-28
• Primary completion: 2023-02-21
• Completion: 2023-03-14
• First posted: 2023-04-07
• Last updated: 2023-04-07

Locations

1 site across 1 country: South Korea